Childhood Osteosarcoma: Multimodal Therapy in a Single-Institution Turkish Series

Part of the Cancer Treatment and Research book series (CTAR, volume 152)


Between January 1990 and December 2006, 123 patients ≤16 years with the histopathologic diagnosis of osteosarcoma were treated with a chemotherapy regimen comprising epirubicin, cisplatin, and ifosfamide. The mean follow-up time was 36 months (range 2-219 months). Among the 94 patients analyzed, 68 patients (72.3%) were alive at the time of the analysis. A total of 26 patients (13 each with nonmetastatic and metastatic disease) died; 20 of these (9 with nonmetastatic disease and 11 with metastatic disease) died of disease; 5, of chemotherapy toxicity, and 1, of nonmetastatic disease from acute nonlymphoid leukemia 13 months following the cessation of osteosarcoma therapy. The estimated 5- and 10-year Overall Survival (OS) rates for all patients were 64.7% (95% confidence interval [95% CI] 74.8-52.94%) and 62.2% (95% CI 74.6-49.9%), respectively. The Event Free Survival (EFS) rate for all patients was 51.8% (95% CI 40.2-63.4%) at both 5 and 10 years. The estimated 5- and 10-year Overall Survival (OS) rates for patients with nonmetastatic disease were 78.3% (95% CI 66.9-89.7%) and 75.1 (95% CI 62.6-87.6%), respectively; this 5-year rate was significantly superior to that of patients with metastatic disease, 13.5% (95% CI 0-30.8%) (p<0.001). The estimated EFS rate for patients with nonmetastatic disease was 62.4% (95% CI 49.9-79.9%) at both 5 and 10 years and was significantly better than the 5-year EFS of 6.9% (95% CI 0-19.9%) in patients with metastatic disease (p<0.001). Progression during preoperative chemotherapy was encountered in 18 patients (19.1%), 11 of whom had metastatic disease at diagnosis. Four patients (three with nonmetastatic disease and one with metastatic disease) underwent salvage treatment consisting of early surgical intervention and preoperative radiation. The estimated 5- and 10-year OS rates were 13% (95% CI 0-29.7%) for patients who had progression during treatment; this rate was significantly inferior to both the 5- and 10-year OS rates for patients without progressive disease, which were 78.2% (95% CI 66.1-90.4%) and 75% (95% CI 61.9-83.1%), respectively (p<0.001). A total of 33 patients experienced relapse and/or progression at a median time of 9 months (range 0-40 months). Histologic response (<90% necrosis vs. ≥90%) was significantly correlated with the 5-year EFS (31% vs. 67.6%, respectively, p=0.023) but not with OS (57.7% vs. 76.5%, respectively, p=0.13). The presence of metastases at diagnosis was found to be the most significant single characteristic influencing the outcome. The rate of histologically good response to preoperative chemotherapy was 64.5%, which is comparable with the 28-85% response rates given in the literature. Our results demonstrate that the combination of epirubicin, cisplatin, and ifosfamide is an active and reasonably well-tolerated regimen for childhood osteosarcoma.


Overall Survival Preoperative Chemotherapy Histologic Response Event Free Survival Mesenchymal Chondrosarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cortes EP, Holland JF, Wang JJ, et al. Doxorubicin in disseminated osteosarcoma. JAMA. 1972;221:1132-1138.CrossRefGoogle Scholar
  2. 2.
    Jaffe N, Farber S, Traggis D, et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer. 1973;31:1367-1373.CrossRefPubMedGoogle Scholar
  3. 3.
    Jaffe N, Frei E III, Traggis D, et al. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: presurgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977;39:45-50.CrossRefPubMedGoogle Scholar
  4. 4.
    Ochs JJ, Freeman AI, Douglass HO Jr, et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep. 1978;62:239-245.PubMedGoogle Scholar
  5. 5.
    Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2177.CrossRefPubMedGoogle Scholar
  6. 6.
    Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115-117.PubMedGoogle Scholar
  7. 7.
    Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol. 1985;3:1101-1104.PubMedGoogle Scholar
  8. 8.
    Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomised cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.PubMedGoogle Scholar
  9. 9.
    Winkler K, Bielac S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66:1703-1710.CrossRefPubMedGoogle Scholar
  10. 10.
    Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.PubMedGoogle Scholar
  11. 11.
    Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458.PubMedGoogle Scholar
  12. 12.
    Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Institute Ortopedico Rizzoli according to the Instituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.PubMedGoogle Scholar
  13. 13.
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-790.CrossRefPubMedGoogle Scholar
  14. 14.
    Meyers PA, Schwartz C, Krailo M, et al. Osteosarcoma: a randomized, prospective trail of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicn, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.CrossRefPubMedGoogle Scholar
  15. 15.
    Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res. 1997;345:206-214.CrossRefPubMedGoogle Scholar
  16. 16.
    Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334-341.CrossRefPubMedGoogle Scholar
  17. 17.
    Claude L, Rousmans S, Carrie C, et al. Standards and options for the use of radiation therapy in the management of patients with osteosarcoma. Update 2004. Cancer Radiother. 2005;9:104-121.PubMedGoogle Scholar
  18. 18.
    Dincbas FO, Koca S, Mandel NM, et al. The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int J Radiat Oncol Biol Phys. 2005;62:820-828.CrossRefPubMedGoogle Scholar
  19. 19.
    Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer. 2008;50:976-982.CrossRefPubMedGoogle Scholar
  20. 20.
    Kutluk T. First national pediatric cancer registry in Turkey: a Turkish Pediatric Oncology Group (TPOG) study XXXVI. International Pediatric Oncology (SIOP) Meeting, Oslo, Norway, Sept 16–19, 2004. Med Pediatr Oncol. 2004;43:146.Google Scholar
  21. 21.
    Topuz E, Ayan İ. University of İstanbul, Institute of Oncology: Center Presentation. Pediatr Hematol Oncol. 1997;14:315-321.CrossRefPubMedGoogle Scholar
  22. 22.
    Ayan İ, Kebudi R, Görgün Ö, et al. Assessment of acute toxicity following cisplatin, epirubicin with/without ifosfamide in children with bone sarcomas. Med Pediatr Oncol. 1996;27:315.Google Scholar
  23. 23.
    Ornadel D, Souhami RL, Whelan J, et al. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol. 1994;12:1842-1848.PubMedGoogle Scholar
  24. 24.
    Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.CrossRefPubMedGoogle Scholar
  25. 25.
    Kantar M, Çetingül N, Azarsız S, et al. Treatment results of osteosarcoma of the extremity in children and adolescents at Ege University Hospital. Pediatr Hematol Oncol. 2002;19:475-482.CrossRefPubMedGoogle Scholar
  26. 26.
    Özkan A, Celkan T, Apak H, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a single Institute from Turkey. Australas J Cancer. 2006;5:325-328.Google Scholar
  27. 27.
    Varan A, Yazıcı N, Aksoy C, et al. Treatment results of pediatric osteosarcoma: twenty-year experience. J Pediatr Orthop. 2007;27:241-246.PubMedGoogle Scholar
  28. 28.
    Petrilli AS, de Camargo B, Filho VO, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24:1161-1168.CrossRefPubMedGoogle Scholar
  29. 29.
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76-84.PubMedGoogle Scholar
  30. 30.
    Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.PubMedGoogle Scholar
  31. 31.
    Özger H, Eralp L, Atalar AC, et al. Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma. Acta Orthop Traumatol Turc. 2007;41:211-219.PubMedGoogle Scholar
  32. 32.
    Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.CrossRefPubMedGoogle Scholar
  33. 33.
    Tokuç G, Doİan Ö, Ayan İ, et al. Prognostic value of proliferating cell nuclear antigen (PCNA) immunostaining in pediatric osteosarcoma. Int J Pediatric Hematol Oncol. 1998;5:373-377.Google Scholar
  34. 34.
    Kebudi R, Ayan İ, Yasasever V, et al. Are serum levels of CD44 relevant in children with pediatric sarcomas? Pediatr Blood Cancer. 2006;1:62-65.CrossRefGoogle Scholar
  35. 35.
    Kebudi R, Ayan İ, Yasasever V, et al. Serum levels of intercellular adhesion molecule 1 (ICAM 1) in pediatric solid tumors. J Tumor Marker Oncol. 2004;19:107-112.Google Scholar
  36. 36.
    Pastorino LI, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol. 1991;9:1357-1362.PubMedGoogle Scholar
  37. 37.
    Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995;75:1084-1093.CrossRefPubMedGoogle Scholar
  38. 38.
    Ferrari S, Bricolli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21:710-715.CrossRefPubMedGoogle Scholar
  39. 39.
    Kebudi R, Ayan İ, Görgün Ö, et al. Brain metastasis in pediatric extracranial malignant tumors. J Neurooncol. 2005;71:43-48.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Pediatric Oncology, Institute of Oncologyİstanbul UniversityİstanbulTurkey

Personalised recommendations